LLY logo Eli Lilly and Company +
Eli Lilly and Company
+

Eli Lilly and Company Overview

Company: Eli Lilly and Company
CEO: David A. Ricks
Founded: 1876
Symbol: LLY
Exchange: NYSE
Industry: Drug Manufacturers - General
Sector: Healthcare
About

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offeringslude a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. Theselude Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant productslude Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners,luding Incyte Corporation; Boehringer Ingelheim Pharmaceuticals; AbCellera Biologics; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics; Kumquat Biosciences; Entos Pharmaceuticals; and Foghorn Therapeutics Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Continue reading...

Eli Lilly and Company (LLY)

  • Stock Price
  • Volume
+972.56 +415.69%
Past 5 Years
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • 10Y
  • ALL

Revenue

Eli Lilly and Company annual revenue was $65.18 B in 2025.

Net Income

Eli Lilly and Company annual net income was $20.64 B in 2025.

Employees

Eli Lilly and Company annual employee count was 50,000 in 2025.

Revenue by Segment

Eli Lilly and Company’s revenue by segment: Collaboration and Other Revenue: $4.22 B and Product: $60.96 B in 2025.

Revenue by Region

Eli Lilly and Company’s revenue by region: CHINA: $1.95 B, Europe: $11.56 B, JAPAN: $2.13 B, Non-US: $6.06 B and UNITED STATES: $43.48 B in 2025.

Executive Salary

David A. Ricks Chair, President, and Chief Executive Officer, at Eli...

Revenue per Employee

Eli Lilly and Company revenue per employee was $1.30 M in 2025.

Profit per Employee

Eli Lilly and Company profit per employee was $412.77 K in 2025.

Income Statement

Operating Income

Eli Lilly and Company annual operating income was $29.70 B in 2025.

Research & Development

Eli Lilly and Company annual research & development expense was $13.34 B in 2025.

Tax Rate (%)

Eli Lilly and Company annual Tax Rate was 20.00% in 2025.

Assets & Liabilities | Cash Flow

Total Assets

Eli Lilly and Company annual total assets was $112.48 B in 2025.

Total Liabilities

Eli Lilly and Company annual total liabilities was $85.94 B in 2025.

Capital Expenditure

Eli Lilly and Company annual capital expenditures was -$7.84 B in 2025.

Ratios

Return on Equity (ROE)

Eli Lilly and Company annual return on equity(ROE) was 0.00% in 2025.

Return on Assets (ROA)

Eli Lilly and Company annual return on assets(ROA) was 0.00% in 2025.

Debt to Equity

Eli Lilly and Company annual debt to equity was 160.18% in 2025.

Profitability

Gross Profit Margin (%)

Eli Lilly and Company annual gross profit margin was 83.79% in 2025.

Operating Income Margin (%)

Eli Lilly and Company annual operating income margin was 45.56% in 2025.

Net Income Margin (%)

Eli Lilly and Company annual net income margin was 31.66% in 2025.

Earning Per Share

Eli Lilly and Company annual earning per share was $22.98 in 2025.

EBITDA

Eli Lilly and Company annual EBITDA was $27.94 B in 2025.

Free Cash Flow (FCF)

Eli Lilly and Company annual free cash flow(FCF) was $8.97 B in 2025.

Valuation

Enterprise value

Eli Lilly and Company annual enterprise value was - in 2025.

Enterprise value to Revenue

Eli Lilly and Company annual enterprise value to revenue was 0.00 in 2025.

Enterprise value to EBITDA

Eli Lilly and Company annual enterprise value to EBITDA was 0.00 in 2025.

Competitors’ Revenue

Frequently Asked Questions

When was Eli Lilly and Company founded?

Eli Lilly and Company was founded on 1876, which makes the company 150 years old.

Sign up for free to view

Who is the CEO of Eli Lilly and Company?

David A. Ricks is the CEO of Eli Lilly and Company.

What industry and sector is Eli Lilly and Company in?

Eli Lilly and Company operates in the Drug Manufacturers - General industry and the Healthcare sector.

What are Eli Lilly and Company's CIK, SIC, and ISIN codes?

  • CIK (Central Index Key): 0000059478
  • SIC (Standard Industrial Classification): 2834
  • ISIN (International Securities Identification Number): US5324571083

Sign up for free to view

How many employees does Eli Lilly and Company have?

Eli Lilly and Company has 50,000 employees.

What is the revenue of Eli Lilly and Company?

In fiscal year 2025, Eli Lilly and Company generated a revenue of $65.18 Billion.

What is the net income of Eli Lilly and Company?

In fiscal year 2025, Eli Lilly and Company reported a net income of $20.64 Billion.

What is Eli Lilly and Company's biggest product segment?

Product is Eli Lilly and Company's biggest product segment, representing 93.52% of its total revenue.

When was Eli Lilly and Company listed on the stock exchange?

Eli Lilly and Company went public on Jun 1, 1972, through its Initial Public Offering (IPO), and it has been 54 years since then.

Sign up for free to view

What is the ticker symbol of Eli Lilly and Company, and where is it listed?

Eli Lilly and Company's ticker symbol is LLY, and the company is listed on the NYSE stock market exchange.

What is Eli Lilly and Company's current stock price?

Eli Lilly and Company's current stock price is $1.21 K as of Jul 2, 2026.

What is Eli Lilly and Company's market capitalization?

As of , Eli Lilly and Company's market cap is .

What is Eli Lilly and Company's ranking in the world?

Ranked #1among 2,795 companies based on market cap.

Who are the top competitors of Eli Lilly and Company?

Competitors of Eli Lilly and Company include Johnson & Johnson, AbbVie and Merck & Co., and more.

People Also Search For

Submit feedback to Bullfincher